Press release
Renin-Angiotensin-System (RAS)-Acting Agents Market Insights Highlight Segment Expansion And Market Leadership
Renin-Angiotensin-System (RAS)-Acting Agents Market
Renin-Angiotensin-System (RAS)-Acting Agents Market Size and Growth Projections
The RAS-acting agents market is on a steady upward trajectory, with its value expected to increase from $6.11 billion in 2025 to $6.44 billion in 2026, representing a compound annual growth rate (CAGR) of 5.5%. This solid growth during the historical period has been propelled by a high incidence of hypertension, a growing elderly population, broad adoption of ACE inhibitors, increased cardiovascular disease screenings, and the availability of affordable generic medications. Looking ahead, the market is forecasted to reach $7.96 billion by 2030 at a slightly moderated CAGR of 5.4%, driven by factors such as the rising burden of chronic kidney disease, growing demand for cardiometabolic therapies, improved patient adherence to treatment regimens, expansion in emerging economies, and the approval of combination drug therapies. Key trends expected to shape the market include a wider use of combination antihypertensive treatments, development of long-acting cardiovascular drugs, increased focus on renal protection, growth in generic RAS drug manufacturing, and a shift towards fixed-dose combination therapies.
Download a free sample of the renin-angiotensin-system (ras)-acting agents market report:
https://thebusinessresearchcompany.com/sample_request?id=85451176&type=smp&name=Renin-Angiotensin-System%20%28RAS%29-Acting%20Agents%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR
Key Factors Propelling the Expansion of the RAS-Acting Agents Market
One prominent factor contributing to the market's growth is the escalating prevalence of chronic kidney disease, which creates a heightened demand for effective renin-angiotensin-system-based medications. These drugs play a crucial role in managing kidney-related complications and offer therapeutic benefits beyond hypertension control. Additionally, the increasing global burden of cardiometabolic diseases fuels the need for targeted treatments that can manage multiple risk factors simultaneously. This demand is further supported by enhanced patient compliance, driven by the introduction of user-friendly drug formulations and fixed-dose combinations designed to simplify treatment regimens.
Emerging pharmaceutical markets and regulatory approvals for combination therapies represent additional growth catalysts. Expanding healthcare infrastructure and greater access to medications in developing regions enable a broader patient base to benefit from RAS-acting agents. Moreover, ongoing clinical advancements and approvals of innovative drug combinations contribute to market momentum by providing more effective and convenient treatment options.
View the full renin-angiotensin-system (ras)-acting agents market report:
https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR
Noteworthy Companies Influencing the RAS-Acting Agents Market Landscape
The competitive landscape of the RAS-acting agents market includes many leading global pharmaceutical companies such as Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., and Zydus Lifesciences Limited.
Strategic Acquisitions Highlight AstraZeneca's Cardiorenal Focus
In February 2023, AstraZeneca strengthened its presence in the cardiorenal sector by acquiring US-based biopharmaceutical firm CinCor Pharma for $1.3 billion. This acquisition brought CinCor's lead candidate, baxdrostat (CIN-107), into AstraZeneca's development pipeline. Baxdrostat is a selective aldosterone synthase inhibitor aimed at treating resistant hypertension by targeting aldosterone synthesis pathways. This move signifies AstraZeneca's commitment to expanding innovative treatment options in the renin-angiotensin-system space and addressing unmet needs in hypertension management.
Upcoming Trends Steering the Future of the RAS-Acting Agents Market
Pharmaceutical companies are focusing heavily on developing next-generation RAS inhibitors, including novel angiotensin-converting enzyme (ACE) inhibitors, to improve treatment outcomes. Efforts are concentrated on enhancing drug efficacy, reducing side effects, and boosting patient adherence. By doing so, these developments aim to better manage hypertension, heart failure, and kidney disease. ACE inhibitors work by blocking the enzyme responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor, thereby relaxing blood vessels and reducing blood pressure.
A recent example illustrating this trend is Proveca Ltd., a UK-based pharmaceutical company that, in November 2023, received a grant from the European Commission for pediatric use marketing authorization of Aqumeldi (enalapril maleate) orodispersible tablets. This medication treats heart failure in children from birth to under 18 years by inhibiting the angiotensin-converting enzyme, improving blood flow, and decreasing the workload on the heart. Such approvals underscore the growing emphasis on tailoring RAS-acting agents for specific patient populations.
Detailed Market Segmentation and Forecast for RAS-Acting Agents
The global RAS-acting agents market is segmented into multiple categories for a comprehensive analysis:
1. By Drug Class:
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Renin Inhibitors
- Aldosterone Antagonists
- Other Drug Classes
2. By Indication:
- Hypertension
- Heart Failure
- Chronic Kidney Disease
- Diabetic Nephropathy
- Coronary Artery Disease
3. By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
4. By End-User:
- Hospitals
- Research Institutes
- Pharmaceutical Companies
- Other End-Users
Further subcategories within drug classes include well-known ACE inhibitors like Captopril, Enalapril, Lisinopril, Ramipril, and Perindopril. The ARB segment features medications such as Losartan, Valsartan, Irbesartan, Olmesartan, and Telmisartan. Renin inhibitors are represented by Aliskiren, while Aldosterone antagonists include Spironolactone and Eplerenone. Other classes cover Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), and Angiotensin Receptor Blockers combined with Neprilysin Inhibitors (ARNBIs).
This detailed segmentation helps stakeholders understand market dynamics and anticipate growth opportunities across various drug types, indications, and distribution channels as the RAS-acting agents market continues to evolve through 2030.
Expanded capabilities in our 2026 market reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renin-Angiotensin-System (RAS)-Acting Agents Market Insights Highlight Segment Expansion And Market Leadership here
News-ID: 4673668 • Views: …
More Releases from The Business Research Company
Sustained Release Excipients Market Intelligence Report Covers Trends, Segments …
The sustained release excipients market has been demonstrating significant growth, driven by advances in pharmaceutical formulations and increasing demand for controlled drug delivery systems. This sector is shaping the future of medication administration by enabling more efficient and patient-friendly treatment options. Let's explore the current market size, driving factors, key players, trends, and important segments that define this market's trajectory.
Sustained Release Excipients Market Size and Growth Expectations
The market for…
Stem Cell Therapy Market Outlook Signals Expansion To $16.12 Billion Through 203 …
The stem cell therapy field is emerging as a rapidly evolving sector within the broader healthcare landscape. Driven by advancements in science and technology, the industry is set to achieve significant milestones in the coming years. This overview delves into the market's size, growth drivers, key players, and prevailing trends shaping its future trajectory.
Projected Market Value and Expansion of the Stem Cell Therapy Market
In recent years, the stem cell…
Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Research Reveals …
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market is witnessing robust expansion as advancements in immunotherapy and neurology continue to evolve. With growing prevalence of autoimmune disorders and innovations in oral treatments, this sector is positioned for steady growth in the coming years. Let's explore the market's current size, key drivers, major players, emerging trends, and segment breakdowns shaping its trajectory.
Sphingosine 1 Phosphate Receptor Modulator Drugs Market Size and…
Space-Based Biopharmaceuticals Market Demonstrates Long-Term Growth Potential At …
The field of space-based biopharmaceuticals is witnessing remarkable growth as the integration of space technologies with drug development opens new frontiers. With increasing investments and innovations, this sector is set to revolutionize how biologics and therapeutics are developed, particularly by leveraging the unique conditions of microgravity. Let's explore the current market dynamics, key players, emerging trends, and future outlook for this rapidly evolving industry.
Space-Based Biopharmaceuticals Market Size and Expected Growth…
More Releases for RAS
Ras Al Khaimah's Trusted Physiotherapy Service
Unlock Your Body's Potential with Physio Home Professional Physiotherapy Services
At Physio Home in Ras Al Khaimah, we understand the pivotal role that physiotherapy plays in enhancing one's quality of life. Our dedicated team of experts is committed to providing personalized care and effective solutions tailored to your unique needs. With a focus on empowering mobility and promoting holistic well-being, we bring top-tier physiotherapy services directly to your doorstep. Whether you're…
Ras Aquaculture Market Leading Players, Competitive Landscape, Strategy, Forecas …
Ras Aquaculture Market Overview:
Recirculating Aquaculture Systems (RAS) represent an innovative and sustainable approach to aquaculture, focusing on the intensive farming of aquatic organisms in a controlled environment. Unlike traditional aquaculture methods that rely heavily on large water bodies, RAS involves the continuous recirculation and treatment of water within a closed-loop system. This method significantly reduces water usage, minimizes environmental impact, and allows for year-round production regardless of external weather conditions.…
RAS Inhibitors Market Size, Share, Growth Analysis 2023
The global ras inhibitors market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of x% during the forecast period 2023-29. Ongoing research and development efforts in the RAS-inhibitors agents market are expanding its scope. New drugs targeting various renin-angiotensin system components, such as renin, ACE, and angiotensin II receptors, are being explored. The market is also witnessing increased interest…
RAS Targeting Therapies Market, 2021-2031 by Roots
Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings.
To order this 140+ page report, which features 95+ figures, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html
Key Inclusions
A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I /…
RAS Luxury Oils Launches Eco drive Campaign
Luxury Natural Skincare and wellness brand promotes Sustainability for the Environment
One Bottle at a Time #RecyclewithRAS
New Delhi, 26th November 2018: “Farm to bottle’ luxury natural skincare and wellness brand RAS Luxury Oils has launched its eco drive campaign, #RecyclewithRAS to encourage customers, to promote the concept of three R’s -“Reduce, Reuse and Recycle”, and to regain the sustainability of the packaging among customers.
On returning 1 empty primary bottle…
The Kurchatov Institute Has Chosen 2X RAS
Kurchatov Institute - supported by Aflex Distribution - Has Chosen 2X Remote Application Server
"We are very positive about the adoption of a 2X solution. At the moment we are using 2X RAS for its main features: application delivery and load balancing. We are very satisfied with the seamless end-user experience and the high availability gained with the workload-based server load balancing. In future, we plan to use 2X RAS…
